Kwangdong Healthbio Co., Ltd. (XKON:086220)
South Korea · Delayed Price · Currency is KRW 1,468.00
-32.00 (-2.13%)
At close: Aug 1, 2025, 3:30 PM KST
Kwangdong Healthbio Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2014 | FY 2013 | FY 2012 | FY 2011 | FY 2010 | 2005 - 2009 |
|---|---|---|---|---|---|---|
Period Ending | Dec '14 Dec 31, 2014 | Dec '13 Dec 31, 2013 | Dec '12 Dec 31, 2012 | Dec '11 Dec 31, 2011 | Dec '10 Dec 31, 2010 | 2005 - 2009 |
Operating Revenue | 38,096 | 31,786 | 35,857 | 29,813 | 46,906 | Upgrade |
Other Revenue | - | 0 | - | 0 | - | Upgrade |
| 38,096 | 31,786 | 35,857 | 29,813 | 46,906 | Upgrade | |
Revenue Growth (YoY) | 19.85% | -11.35% | 20.27% | -36.44% | 1.14% | Upgrade |
Cost of Revenue | 33,042 | 26,154 | 29,957 | 24,645 | 39,200 | Upgrade |
Gross Profit | 5,054 | 5,632 | 5,900 | 5,168 | 7,707 | Upgrade |
Selling, General & Admin | 2,996 | 3,168 | 3,484 | 2,338 | 5,782 | Upgrade |
Other Operating Expenses | - | - | - | - | -0 | Upgrade |
Operating Expenses | 4,027 | 4,790 | 4,203 | 2,433 | 5,877 | Upgrade |
Operating Income | 1,027 | 842.11 | 1,697 | 2,735 | 1,829 | Upgrade |
Interest Expense | -957.97 | -1,272 | -2,079 | -1,969 | -2,170 | Upgrade |
Interest & Investment Income | 11.51 | 116.66 | 204.31 | 351.11 | 734.57 | Upgrade |
Currency Exchange Gain (Loss) | -16.98 | 168.44 | 428.37 | -227.34 | -374.38 | Upgrade |
Other Non Operating Income (Expenses) | -151.03 | -68.01 | 233.98 | 18.82 | -195.14 | Upgrade |
EBT Excluding Unusual Items | -87.78 | -212.38 | 485.04 | 908.91 | -175.44 | Upgrade |
Gain (Loss) on Sale of Investments | -182.53 | -60 | - | - | - | Upgrade |
Gain (Loss) on Sale of Assets | -7.4 | 3.68 | 19.22 | -0.46 | 172 | Upgrade |
Asset Writedown | - | - | - | - | -2,109 | Upgrade |
Pretax Income | -277.71 | -268.71 | 504.26 | 908.46 | -2,113 | Upgrade |
Income Tax Expense | 45.81 | 111.99 | 148.58 | 167.83 | -290.72 | Upgrade |
Earnings From Continuing Operations | -323.52 | -380.7 | 355.68 | 740.63 | -1,822 | Upgrade |
Earnings From Discontinued Operations | - | - | 110.36 | 89.75 | - | Upgrade |
Net Income | -323.52 | -380.7 | 466.04 | 830.38 | -1,822 | Upgrade |
Net Income to Common | -323.52 | -380.7 | 466.04 | 830.38 | -1,822 | Upgrade |
Net Income Growth | - | - | -43.88% | - | - | Upgrade |
Shares Outstanding (Basic) | 6 | 6 | 7 | 8 | 8 | Upgrade |
Shares Outstanding (Diluted) | 6 | 6 | 7 | 8 | 8 | Upgrade |
Shares Change (YoY) | 2.87% | -23.05% | -15.38% | 0.46% | -0.23% | Upgrade |
EPS (Basic) | -57.00 | -69.00 | 65.00 | 98.00 | -216.00 | Upgrade |
EPS (Diluted) | -57.00 | -69.00 | 65.00 | 98.00 | -216.00 | Upgrade |
EPS Growth | - | - | -33.67% | - | - | Upgrade |
Free Cash Flow | 350.26 | 1,854 | -844.74 | -6,018 | 2,630 | Upgrade |
Free Cash Flow Per Share | 61.71 | 336.00 | -117.82 | -710.23 | 311.76 | Upgrade |
Gross Margin | 13.27% | 17.72% | 16.45% | 17.34% | 16.43% | Upgrade |
Operating Margin | 2.70% | 2.65% | 4.73% | 9.17% | 3.90% | Upgrade |
Profit Margin | -0.85% | -1.20% | 1.30% | 2.79% | -3.88% | Upgrade |
Free Cash Flow Margin | 0.92% | 5.83% | -2.36% | -20.18% | 5.61% | Upgrade |
EBITDA | 2,656 | 2,443 | 3,256 | 4,059 | 2,960 | Upgrade |
EBITDA Margin | 6.97% | 7.69% | 9.08% | 13.61% | 6.31% | Upgrade |
D&A For EBITDA | 1,629 | 1,601 | 1,559 | 1,324 | 1,131 | Upgrade |
EBIT | 1,027 | 842.11 | 1,697 | 2,735 | 1,829 | Upgrade |
EBIT Margin | 2.70% | 2.65% | 4.73% | 9.17% | 3.90% | Upgrade |
Effective Tax Rate | - | - | 29.47% | 18.47% | - | Upgrade |
Advertising Expenses | 60.47 | 19.7 | 96.15 | 57.35 | 91.85 | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.